Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers

European Journal of Clinical Chemistry and Clinical Biochemistry

Volumn 34, Issue 10, 1996, Pages 785-799

  Withold, Wolfgang ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Institut fur Pharmakologie und Klinische Pharmakologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; COLLAGEN TYPE 1; HYDROXYPROLINE; LIVER ENZYME; OSTEOCALCIN; PROCOLLAGEN; PYRIDINIUM DERIVATIVE;

ANALYTIC METHOD; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CROSS REACTION; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; IMMUNOCHEMISTRY; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

ACID PHOSPHATASE; ADULT; ALKALINE PHOSPHATASE; AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL MARKERS; BONE DISEASES; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; MALE; MENOPAUSE; MOLECULAR SEQUENCE DATA; OSTEOCALCIN; OSTEONECTIN; PEPTIDES; PYRIDINIUM COMPOUNDS; SIALOGLYCOPROTEINS; TARTRATES;

EID: 0029827589     PISSN: 09394974     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. de Vernejoul MC. Dynamics of bone remodeling: biochemical and pathophysiological basis [review]. Eur J Clin Chem Clin Biochem 1996; 34:729-34.
2. Eriksen EF, Brixen K, Charles P. New markers of bone metabolism: clinical use in metabolic bone disease [review]. Eur J Endocrinol 1995; 132:251-63.
3. Moss DW. Perspectives on alkaline phosphatase research [review]. Clin Chem 1992; 38:2486-92.
4. Miura M, Sakagishi Y, Hata K, Komoda T. Differences between the sugar moieties of liver- and bone-type alkaline phosphatases: a re-evaluation. Ann Clin Biochem 1994; 31:25-30.
5. van Hoof VO, de Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sei 1994; 31:197-293.
6. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone diseases. J Clin Endocrinol Metab 1993; 77:1046-53.
7. Gomez B. Ardakani S, Ju J. Jenkins D, Cerelli MJ, Daniloff GY, et al. Monoclonal antibody assay for monitoring bonespecific alkaline phosphatase activity in serum. Clin Chem 1995; 41:1560-6.
8. Withold W. Rick W. Evaluation of an immunoradiometric assay for bone alkaline phosphatase mass concentration in human sera. Eur J Clin Chem Clin Biochem 1994; 32:91-5.
9. Panigrahi K, Delmas PD, Singer F, Ryan W. Reiss O, Fisher R. et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 1994:40:822-8.
10. England TE, Samsoondar J, Maw G. Evaluation of the Hybritech Tandem-R Ostase immunoradiometric assay for skeletal alkaline phosphatase. Clin Biochem 1994; 27:187-9.
11. Parley JR, Hall SL, Ilacas D, Orcutt C, Miller BE, Hill CS, et al. Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin, heat inactivation, and a two-site immunoradiometric assay. Clin Chem 1994; 40:1749-56.
12. Withold W, Schulte U. Reinauer H. Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Clin Chem 1996; 42:210-7.
13. Behr W. Bernert J. Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility. Clin Chem 1986; 32:1960-6.
14. Rosalki SB, Ying Foo A, Burlina A, Prellwitz W, Stieber P, Neumeier D, et al. Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma. Clin Chem 1993; 39:648-52.
15. Langlois MR, Delanghe JR, Kaufman JM, de Buyzere ML, van Hoecke MJ, Leroux-Roels GO. Posttranslational heterogeneity of bone alkaline phosphatase in metabolic bone diseases. Eur J Clin Chem Clin Biochem 1994; 32:675-80.
16. van Hoof VO, van Müllern M, de Broe ME, Lepoutre LG. Comparison of two commercially available systems for the electrophoretic separation of alkaline phosphatase isoenzymes. J Chromatogr 1993; 646:235-43.
17. Magnusson P, Lofrnan O, Larsson L. Determination of alkaline phosphatase isocnzymes in serum by high-performance liquid chromatography with post-column reaction detection. J Chromatogr 1992; 576:79-86.
18. Heins M. Heil W, Withold W. Storage of serum or whole blood samples? Effects of time and temperature on 22 serum analytes. Eur J Clin Chem Clin Biochem 1995; 33:231-8.
19. Crofton PM, Stirling HF, Kelnar CJH. Bone alkaline phosphatase and height velocity in short normal children undergoing growth-promoting treatments: longitudinal study. Clin Chem 1995; 41:672-8.
20. Garnero P, Sornayrendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. Bone 1995; 16:499-503.
21. Pedersen BJ, Schlemmer A, Hassager C, Christiansen C. Changes in the carboxyl-terminal propeptide of type I procollagen and other markers of bone formation upon five days of bed rest. Bone 1995; 17:91-5.
22. Withold W, Degenhardt S, Castelli D, Heins M, Grabensee B. Monitoring of osteoblast activity with an immunoradiometric assay for determination of bone alkaline phosphatase mass concentration in patients receiving renal transplants. Clin Chim Acta 1994; 225:137-46.
23. Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 1994; 25:236-42.
24. Braga V, Dorizzi R, Brocco G, Rossini M, Zamberlan N, Gatti D, et al. Clinical utility of a wheat-germ precipitation assay for determination of bone alkaline phosphatase concentration in patients with different metabolic bone diseases. Eur J Clin Chem Clin Biochem 1995; 33:433-9.
25. Withold W, Georgescu G, Khakzad H, Vosberg H, MuellerGaertner HW, Reinauer H. Simultaneous assessment of bone collagen synthesis and degradation in patients with different malignant tumours: comparison with the results of 99mTcmethylene bisphosphonate bone scintigraphy. Eur J Clin Chem Clin Biochem 1995; 33:479-85.
26. Withold W, Georgescu G, Khakzad H, Vosberg H, MuellerGaertner HW, Reinauer H. Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone métastases. Clin Biochem 1995; 28:511-8.
27. van Hoof VO, Martin M, Blockx P, Prove A, van Oosterom A, Couttenye MM, et al. Immunoradiometric method and electrophoretic system compared for quantifying bone alkaline phosphatase in serum. Clin Chem 1995; 41:853 -7.
28. Epstein S. Serum and urinary markers of bone remodeling: assessment of bone turnover [review]. Endocrine Rev 1988; 9:437-49.
29. Diego EMD, Guerrero R, de la Piedra C. Six osteocalcin assays compared. Clin Chem 1994; 40:2071-7.
30. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994; 9:255-64.
31. Masters PW, Jones RG, Purves DA, Cooper EH, Cooney JM. Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 1994; 40:358-63.
32. Deftos LJ, Wolfert RL, Hill CS, Burton DW. Two-site assays of bone gla protein (osteocalcin) demonstrate immunochemical heterogeneity of the intact molecule. Clin Chem 1992; 38:2318-21.
33. Sokoll LJ, O'Brien ME, Camilo ME, Sadowski JA. Undercarboxylated osteocalcin and development of a method to determine vitamin K status. Clin Chem 1995; 41:1121-8.
34. Banfi G, Daverio R. In vitro stability of osteocalcin [letter]. Clin Chem 1994; 40:833-4.
35. Power MJ, O'Dwyer B, Breen E, Fottrell PF. Osteocalcin concentrations in plasma prepared with different anticoagulants. Clin Chem 1991; 37:281-4.
36. Durham BH, Robinson J, Fraser WD. Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. Ann Clin Biochem 1995; 32:422-3.
37. Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439-45.
38. Blumsohn A, Hannon RA, Eastell R. Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin Chem 1995; 41:318 -9.
39. Delmas PD. Biochemical markers of bone turnover [review]. Acta Orthop Scand 1995; 66:176-82.
40. Schlemmer A, Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C. Possible variation in bone résorption during the normal menstrual cycle. Acta Endocrinol (Copenh) 1993; 129:388-92.
41. Michaelsson K, Holmberg L, Mallmin H, Wölk A, Bergstrom R, Ljunghall S. Diet, bone mass, and osteocalcin: a crosssectional study. Calcif Tissue Int 1995; 57:86-93.
42. Karlsson MK, Vergnaud P, Delmas PD, Obrant KJ. Indicators of bone formation in weight lifters. Calcif Tissue Int 1995; 56:177-80.
43. Panteghini M, Pagani F. Biological variation in bone-derived biochemical markers in serum. Scand J Clin Lab Invest 1995; 55:609-15.
44. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metabol 1994; 79:1693700.
45. Diego EMD, Martin MAD, Delapiedra C, Rapado A. Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic women. Horm Metab Res 1995; 27:151-4.
46. Bouman AA, Scheffer PG, Ooms ME, Lips P, Netelenbos C. Two bone alkaline phosphatase assays compared with osteocalcin as a marker of bone formation in healthy elderly women. Clin Chem 1995; 41:196-9.
47. Duda RJ, O'Brien JF, Katzmann JA, Peterson JM, Mann KG, Riggs BL. Concurrent assays of circulating bone glaprotein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab 1988; 66:951-7.
48. Delmas PD. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 1990; 19:1-18.
49. Peretz A, Moris M, Willems D, Bergmann P. Is bone alkaline phosphatase an adequate marker of bone metabolism during acute corticosteroid treatment? Clin Chem 1996; 42:102-3.
50. Schmidt H, Stracke H, Schatz H, Scheuermann EH, Fassbinder W, Schoeppe W. Osteocalcin serum levels in patients following renal transplantation. Klin Wochenschr 1989; 67:297-303.
51. Douglas AS, Robins SP, Hutchinson JD, Porter RW, Stewart A, Reid DM. Carboxylation of osteocalcin in post-menopausal osteoporotic women. Bone 1995; 17:15-20.
52. Keim RJ, Hair GA, Mann KG, Grant BW. Characterization of human osteoblast and megakaryocyte-derived osteonectin (SPARC). Blood 1992; 80:3112-9.
53. Serra M, Morini MC, Scotlandi K, Fisher LW, Zini N, Colombo MP, et al. Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. Hum Pathol 1992; 23:1326-31.
54. Malaval L, Ffrench M, Delmas PD. Circulating levels of osteonectin in normal subjects and patients with thrombocytopenia. Bone Miner 1990; 9:129-35.
55. Stenner DD, Tracy RP, Riggs BL, Mann KG. Human platelets contain and secrete osteonectin, a major protein in mineralized bone. Proc Natl Acad Sei USA 1986; 83:6892-6.
56. Young MF, Kerr JM, Ibaraki K, Heegaard AM, Robey PG. Structure, expression, and regulation of the major noncollageneous matrix proteins of bone. Clin Orthop 1992; 281:275-94.
57. Masi L, Brandi ML, Robey PG, Crescioli C, Calvo JC, Bernabei P, et al. Biosynthesis of bone sialoprotein by a human osteoclast-like cell line (FLG 29.1). J Bone Miner Res 1995; 10:187-96.
58. Hunter GK, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. Biochem J 1994; 302:175-9.
59. Roach HI. Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and résorption. Cell Biol Int 1994; 18:617-28.
60. Sodek J, Kim RH, Ogata Y, Li J, Yamauchi M, Zhang Q, et al. Regulation of bone sialoprotein gene transcription by steorid hormones. Connect Tissue Res 1995; 32:209-17.
61. Mansson B, Carey D, Alini M, lonescu M, Rosenberg LC, Poole AP, et al. Cartilage and bone metabolism in rheumatoid arthritis: differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95:1071-7.
62. Saxne T, Zunino L, Heinegard D. Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. Arthritis Rheum 1995; 38:82-90.
63. Prockop DJ, Kivirikko KJ, Tuderman L, Guzman NA. The biosynthesis of collagen and its disorders [review]. New Engl JMed 1978; 301:13-23.
64. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36:1328-32.
65. Scanti I, Monti M, Vigano A, d'Aprile E, Rampoldi E, Castellani L, et al. Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone métastases. Int J Biol Markers 1995; 10:107-12.
66. Pedersen BJ, Bonde M. Purification of human procollagen type 1 carboxy-terminal propeptide cleaved as in vivo from procollagen and used to calibrate a radioimmunoassay of the propeptide. Clin Chem 1994; 40:811-6.
67. Withold W, Degenhardt S, Grabensee B, Reinauer H. Comparison between serum levels of bone alkaline phosphatase and the carboxy-terminal propeptide of type I procollagen as markers of bone formation in patients following renal transplantation. Clin Chim Acta 1995; 239:143-51.
68. Withold W, Wolf HH, Kollbach S, Heyll A, Schneider W, Reinauer H. Monitoring of bone metabolism after bone marrow transplantation by measuring two different markers of bone turnover. Eur J Clin Chem Clin Biochem 1996; 34:193-7.
69. Autio P, Risteli J, Kiistala U, Risteli L, Karvonen J, Oikarinen A. Serum markers of collagen synthesis and degradation in skin diseases: altered levels in diseases with systemic manifestation and during systemic glucocorticoid treatment. Arch Dermatol Res 1993; 285:322-7.
70. Scheja A, Hellmer G, Wollheim FA, Akesson A. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease. Br J Rheumatol 1993; 32:59-62.
71. Host NB, Stoltenberg MB, Jensen LT, Larsen OG, Aurup P. Effect on collagen metabolism of thrombolytic therapy with tissue-plasminogen activator: a randomized, placebo-controlled study. Eur J Clin Invest 1995; 25:15-8.
72. Peuhkurinen KJ, Risteli L, Melkko JT, Linnaluoto M, Jounela A, Risteli J. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation 1991; 83:1969-75.
73. Smedsrod B. Clearance of bone markers from the circulation. Scand J Clin Lab Invest 1995; 223 Suppl 55:130.
74. Kjeldsen J, Demuckadell OSB, Junker P. Seromarkers of collagen I and 111 metabolism in active Crohns disease: relation to disease activity and response to therapy. Gut 1995; 37:805-10.
75. Hamdi NA, Risteli J, Risteli L, Harris S, Beneton MN, Brown CB, et al. Serum type I collagen peptide: a non-invasive index of bone formation in patients on haemodialysis? Nephrol Dial Transplant 1994; 9:511-6.
76. Tokita A, Kelly PJ, Nguyen TV, Qi JC, Morrison NA, Risteli L, et al. Genetic influences on type I collagen synthesis and degradation: further evidence for genetic regulation of bone turnover. J Clin Endocrinol Metab 1994; 78:1461-6.
77. Garnero P, Arden NK, Griffiths G, Delmas PD, Spector TD. Genetic influence on bone turnover in postmenopausal twins. J Clin Endocrinol Metab 1996; 81:140-6.
78. Sorva A, Tahtela R, Risteli J, Risteli L, Laitinen K, JuntunenBackman K, et al. Familial high serum concentrations of the carboxy-terminal propeptide of type I procollagen. Clin Chem 1994; 40:1591-3.
79. Hassager C, Risteli J, Risteli L, Jensen SB, Christansen C. Diurnal variation in serum markers of type I collagen synthe-sis and degradation in healthy premenopausal women. J Bone Miner Res 1992; 7:1307-11.
80. Sgherzi MR, Fabbri G, Bonati M, Maietta-Latessa A, Segre A, de Vita D, et al. Episodic changes of serum procollagen type I carboxy-terminal propeptide levels in fertile and postmenopausal women. Gynecol Obstet Invest 1994; 38:60-4.
81. Kristoffersson A, Hultdin J, Holmlund I, Thorsen K, Lorentzon R. Effects of short-term maximal work on plasma calcium, parathyroid hormone, osteocalcin and biochemical markers of collagen metabolism. Int J Sports Med 1995; 16:145-9.
82. Lieuwafa M, Sierra RI, Specker BL. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. J Bone Miner Res 1995; 10:849-53.
83. Hassager C, Fabbri-Mabelli G, Christiansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen. Osteopor Int 1993; 3:50-2.
84. Brahm H, Ljunggren O, Larsson K, Lindh E, Ljunghall S. Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen. Calcif Tissue Int 1994; 55:412-6.
85. Minisola S, Romagnoli E, Scarnecchia L, Rosso R, Pacitti MT, Scarda A, et al. Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery. Eur J Endocrinol 1994; 130:587-91.
86. Li F, Iqbal J, Wassif W, Kaddam I, Moniz C. Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int 1994; 55:90-3.
87. Mazzaferro S, Pasquali M, Ballanti P, Bonucci E, Constantini S, Chicca S, et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 1995; 10:52-8.
88. Legovini P, de Menis E, da Rin G, Roiter I, Breda F, Artuso V, et al. Increased serum levels of carboxyterminal propeptide of type I collagen (PICP) in hyperthyroidism. Horm Metab Res 1994; 26:334-7.
89. Saggese G, Baroncelli Gl, Bertelloni S, Cinquanta L, di Nero G. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normals and growth-retarded children. Pediatr Res 1994; 35:409-15.
90. Piovesan A. Terzolo M, Reimondo G, Pia A, Codegone A, Osella G, et al. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Horm Metab Res 1994; 26:234-7.
91. Plebani M, Bernardi D, Zaninotto, De Paoli M, Secchiero S, Sciacovelli L. New and traditional serum markers of bone metabolism in the detection of skeletal métastases. Clin Biochem 1996; 29:67-72.
92. Abildgaard N, Nielsen JL, Heickendorff L. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagen, type I collagen telopeptide, and hyaluron. Am J Hematol 1994; 46:173-8.
93. Minisola S, Piccioni AL, Rosso R, Romagnoli E, Pacitti MT, Scarnecchia L, et al. Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta. Metabolism 1994; 43:1261-5.
94. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone résorption in metabolic bone disease. Bone Miner 1990; 8:87-96.
95. Niwa T, Shiobara K, Hamada T, Miyazaki T, Tsukushi S, Uema K. Serum pyridinolines as specific markers of bone résorption in hemodialyzed patients. Clin Chim Acta 1995; 235:33-40.
96. Sinigaglia L, Varenna M, Binelli L, Bartucci F, Arrigoni M, Ferrara R, et al. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1995; 54:144-7.
97. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone résorption. J Bone Miner Res 1994; 9:1643-9.
98. Blumsohn A, Naylor KE, Assiri AMA, Eastell R. Different responses of biochemical markers of bone résorption to bisphosphonate therapy in Paget disease. Clin Chem 1995; 41:1592-8.
99. Kamel S, Brazier M, Neri V, Picard C, Samson L, Desmet G, et al. Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by Chromatographie and immunoassay methods. J Bone Miner Res 1995; 10:138592.
100. Seyedin SM, Kung VT, Daniloff YN, Hesley RP, Gomez B, Nielsen LA, et al. Immunoassay for urinary pyridinoline: the new marker of bone résorption. J Bone Miner Res 1993; 8:635-41.
101. Calebresi E, Lasagni L, Franceschelli F, de Leonardis V, Becorpi A, Serio M, et al. Comparison of immuno- and HPLCassays for the measurement of urinary collagen cross-links. J Endocrinol Invest 1994; 17:625-9.
102. Walne AJ, James IT, Percett D. The stability of pyridinium cross-links in urine and serum [letter]. Clin Chim Acta 1995; 240:95-7.
103. Gerrits MI, Thijssen JHH, van Rijn HJM. Determination of pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability. Clin Chem 1995; 41:571-4.
104. Abbiati G, Bartucci F, Longoni A, Fincato G, Galimberti S, Rigoldi M, et al. Monitoring of free and total urinary pyridinoline and deoxypyridinoline in healthy volunteers: sample relationships between 24-h and fasting early morning urine concentrations. Bone Miner 1993; 21:9-19.
105. Schlemmer A, Hassager C, Jensen SB, Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992; 74:476-80.
106. Schlemmer A, Hassager C, Pedersen BJ, Christiansen C. Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium cross-links. J Bone Miner Res 1994; 9:1883-8.
107. Blumsohn A, Herrington K, Hannon RA, Shao P, Eyre DR, Eastell R. The effect of calcium supplementation on the circadian rhythm of bone résorption. J Clin Endocrinol Metab 1994; 79:7305.
108. Shapses SA, Robins SP, Schwartz El, Chowdhury H. Shortterm changes in calcium but not protein intake alter the rate of bone résorption in healthy subjects as assessed by urinary pyridinium cross-links excretion. J Nutr 1995; 125:2814-21.
109. Colwell A, Russell GG, Eastell R. Factors affecting the assay of urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone résorption. Eur J Clin Invest 1993; 23:341-9.
110. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 1993; 8:643-8.
111. Fujimoto S, Kubo T, Tanaka H, Miura M, Seino Y. Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency. J Clin Endocrinol Metab 1995; 80:1922-8.
112. Gallacher SJ, Fraser WD, Owens JO, Dryburgh FJ, Logue FC, Jenkins A, et al. Changes in calciotrophic hormones and biochemical markers of bone turnover in normal human pregnancy. Eur J Clin Endocrinol 1994; 131:369-74.
113. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian J. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992; 74:481-6.
114. Urena P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 1995; 10:932-9.
115. Withold W, Degenhardt S, Heins M, Grabensee B, Reinauer H. Monitoring of bone résorption after renal transplantation by measuring the urinary excretion of pyridinium cross-links. Eur J Clin Chem Clin Biochem 1995; 33:15-21.
116. Kamel S, Brazier M, Picard C. Boitte F, Samson L, Desmet G, et al. Urinary excretion of pyridinolines crosslinks measured by immunoassay and HPLC techniques in normal subjects and in elderly patients with vitamin D deficiency. Bone Miner 1994; 26:197-208.
117. Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone résorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993; 7:881-9.
118. Seibel MJ, Woitge H, Scheidt-Nave C, Seidig-Bruckner G, Duncan A, Nicol P, et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994; 9:1433-40.
119. AJvarez L, Guanabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995; 10:458-65.
120. Seibel MJ, Duncan A, Robins SP. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 1989; 16:964-70.
121. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone résorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Min Res 1992; 7:125-8.
122. Bollen AM, Martin MD, Leroux BG, Eyre DR. Circadian variation in urinary excretion of bone collagen cross-links. J Bone Miner Res 1995; 10:1885-90.
123. Gorai I, Chaki O, Nakayama M, Minaguchi H. Urinary biochemical markers for bone résorption during the menstrual cycle. Calcif Tissue Int 1995; 57:1004.
124. Sone T, Miyake M, Takeda N, Fukunaga M. Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age and sex-related changes and reference limits. Bone 1995; 17:335-9.
125. Bollen AM, Eyre DR. Bone résorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 1994; 15:31-4.
126. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, et al. Monitoring bone résorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994; 9:135-42.
127. Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, et al. The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994; 79:366-71.
128. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Im 1994; 54:26-9.
129. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonates and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995; 10:641-9.
130. Robins SP, Seibel MJ. Biochemical markers of bone metabolism: a critical evaluation. Clin Lab 1995; 41:987-9.
131. Deniers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995; 41:1489-94.
132. Withold W, Friedrich W, Reinauer H. Comparison of biochemical markers of bone résorption in patients with metabolic and malignant bone diseases. Ann Clin Biochem 1996; 33. In press.
133. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40:2022-5.
134. Silsand T, Reine A, Dugal S, Lunde T, Smedsrud B, Seeberg T. Urinary excretion of a specific peptide of type I collagen of bone (CrossLaps): correlation to hydroxyproline. Scand J Clin Lab Invest 1995; 55:187-92.
135. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone résorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80:864-8.
136. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone résorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994; 79:780-5.
137. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39:635-40.
138. Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 1992; 7:1307-11.
139. Santala M, Risteli L, Puistola U, Risteli J, Kauppila A. Elevated serum ICTP concentrations reflect poor prognosis in patients with ovarian carcinoma. Ann Med 1995; 27:57-61.
140. Wenisch C, Bankl HC, Schonthal E, Myskiw D, Presterl E, Rumpold H, et al. Serum levels of the carboxy-terminal crosslinked telopeptide of type I collagen and laminin are elevated in Graves disease but not in toxic nodular goiter. Clin Immunol Immunopathol 1995; 75:225-30.
141. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischémie dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Card 1995; 75:913-8.
142. Taimela E, Taimela S, Nikkanen V, Irjala K. Accelerated bone degradation in thyroid carcinoma patients during thyroxine treatment, measured by determination of the carboxyterminal telopeptide region of type I collagen in serum. Eur J C!in Chem Clin Biochem 1994; 32:827-31.
143. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentrations of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992; 66:337-41.
144. Hakala M, Aman S, Luukkainen R, Risteli L, Kauppi M, Nieminen P, et al. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54:886-90.
145. Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type 1 collagen in patients with inflammatory bowel disease. Gut 1996; 38:223-8.
146. Koizumi M, Yamada Y, Takiguchi T, Nomura E, Furukawa M, Kitahara T, et al. Bone metabolic markers in bone métastases. J Cancer Res Clin Oncol 1995; 121:542-8.
147. Price CP, Kirwan A, Vader C. Tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 1991; 51:517-24.
148. Scarnecchia L, Minisola S, Pacitti MT, Carnevale V, Romagnoli E, Rosso R, et al. Clinical usefulness of serum tartrateresistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 1991; 51:517-24.
149. Cheung CK, Panesar NS, Haines C, Masarei J, Swaminathan R. Immunoassay of tartrate-resistant acid phosphatase in serum. Clin Chem 1995; 41:679-86.
150. Chamberlain P, Compston J, Cox TM, Hayman AR, Imrie RC, Reynolds K, et al. Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Clin Chem 1995; 41:1495-9.